Direct to Patient Contact Webinar: How Routine Patient Contact Reduces Patient Loss & Costs in Long-Term Studies
June 22 @ 10:00 - 11:00 UTC+0
Because loss to follow up and patients’ withdrawals is a constant concern in clinical studies, we invite you to join our 1-hour session webinar about patient retention risk mitigation strategies.
In addition to study outcomes concerns arising from patients lost to follow-up (LFU) in clinical studies, the financial impact of LFU can be significant. The objectives of this webinar is to determine the cost of patients lost to follow-up (LFU) and financial benefits that can be expected from LFU minimization through Direct to Patient Contact support and services.
Clinical studies that are truly patient-centered cannot be accomplished without active patient insight, engagement, participation and retention; the Pharmaceutical Industry is invited to work more strategically on the patient perspective.
This Mapi webinar will help you understand the added value and return on investment of Direct to Patient Contact (DPC) strategies to properly achieve study objectives as well as Health Authorities’ requirements.
In this one hour session we will provide an overview of:
- What challenges should trigger a DPC approach and proposed solutions
- Benefits of a DPC approach to optimize study outcomes and overall study cost
- Operational approaches of CROs and the pharmaceutical industry
- Lessons learned, results and Return On Investment of a DPC strategy
Janick Michel - Global Director, Direct to Patient Contact, Mapi
- Janick Michel, Global Director of Direct to Patient Contact at Mapi Group, has broad experience in clinical and post-marketing studies for 18+ years. Janick’s expertise includes direct patient experience gained in moderation of patients’ interviews and focus groups and in CRO industry. She has dedicated the past 10 years to patient centered activities mainly in the Real World Evidence setting by implementing strategies for patient recruitment and retention for domestic and global phase II to post-marketing programs across multiple therapeutic areas. Janick has a particular interest in data protection regulation matters. She has a Postgraduate degree of International Communication and Translation in Health Sciences from the Lyon II University, France.
Marsha Jones - Director of Safety and Pharmacovigilance, Mapi
Who Should Attend:
This presentation is designed for participants in the healthcare industry involved in Real World Evidence, patient-centered and patient-reported outcomes approaches, phase II/IV trials, NIS, PASS, PAES, and Registries.